Insight Into the Molecular Mechanism of Podophyllotoxin Derivatives as Anticancer Drugs

Podophyllotoxin (PTOX) is a biologically active compound derived from the podophyllum plant, and both it and its derivatives possess excellent antitumor activity. The PTOX derivatives etoposide (VP-16) and teniposide (VM-26) have been approved by the U.S. Food and Drug Administration (FDA) for cancer treatment, but are far from perfect. Hence, numerous PTOX derivatives have been developed to address the major limitations of PTOX, such as systemic toxicity, drug resistance, and low bioavailability. Regarding their anticancer mechanism, extensive studies have revealed that PTOX derivatives can induce cell cycle G2/M arrest and DNA/RNA breaks by targeting tubulin and topoisomerase II, respectively. However, few studies are dedicated to exploring the interactions between PTOX derivatives and downstream cancer-related signaling pathways, which is reasonably important for gaining insight into the role of PTOX. This review provides a comprehensive analysis of the role of PTOX derivatives in the biological behavior of tumors and potential molecular signaling pathways, aiming to help researchers design and develop better PTOX derivatives.


INTRODUCTION
Cancer remains one of the most concerning issues, affecting millions of people worldwide, and chemotherapy is the mainstay of cancer treatment approaches (Wilson et al., 2019). Although a large number of anticancer drugs have been applied in clinical practice, their application is greatly limited by side effects (Kartal-Yandim et al., 2016). Therefore, studies have been conducted to develop new anticancer therapeutic agents with low systemic toxicity and selective toxicity to cancer cells.
Natural products are already being used to develop molecules with optimal pharmacological properties against various diseases, including cancer. Podophyllotoxin (PTOX) is a wellknown naturally aryltetralinlignane extracted from Podophyllum peltatum and is used as a chemotherapeutic agent for a variety of cancers . In clinical treatment, PTOX derivatives such as etoposide  and teniposide  are used as chemotherapeutic agents, such as the management of small cell lung cancer (Clark and Slevin, 1987;Paz-Ares et al., 2019). However, the limitations of these drugs are prominent, such as poor bioavailability and drug resistance, which necessitate the development of new PTOX-based anticancer drugs.
Currently, many PTOX derivatives have been developed by improving the chemical structure or by conjugation with other molecules, thus allowing to achieve better biological properties.
A large number of novel PTOX derivatives have been designed, synthesized, and used in the treatment of multiple cancers. This review aims to summarize the application of PTOX derivatives in different cancers and to comprehensively analyze the mechanisms of their anticancer functions at the molecular level, which will help researchers develop more favorable PTOX derivatives ( Table 1).

PODOPHYLLOTOXIN AND ITS DERIVATIVES
Podophyllotoxin (PTOX) is found in podophyllum resin from Podophyllum plants and is a subclass of lignans, which refer to a group of plant secondary metabolites. The PTOX structure consists of a dimeric backbone, which is formed by a β-β'linkage between two phenylpropane units, representing a typical structure of lignans. In addition, PTOX includes all the functional groups of arylnaphthalenes lignans and is composed of five rings with four chiral centers, an aryl-tetrahydrofuran type backbone, and a trans-lactone. Therefore, PTOX and its derivatives show great potential as ideal chemical agents for the exploitation of anticancer drugs.
With the development of facile synthesis methods and advances in analytical techniques such as X-ray crystallography, more and more PTOXs have been designed and developed. PTOX as a chemotherapeutic agent along with its β-configuration derivative epipodophyllotoxin are the most basic compounds used for modification to obtain better antitumor agents (Figure 1). As shown in Figure 1, the C ring and its C-4 is the major position used for conjugation with other molecule. Hybrid molecules, conjugated with other pharmacologically active molecules, may reduce the known side effects of the individual molecules and have improved anticancer ability. For instance, the poor water solubility of PTOX can be improved when hybridized with polyethylene glycol (PEG) groups (Pasut and Veronese, 2009). Plus, amino acids or peptides, which are widely used as hybrid molecules, can effectively improve the ability of drugs to cross tumor cell membranes (Hamley, 2017). Furthermore, the most common hybridization strategy is to combine PTOX with another anticancer agent, thereby obtaining better antitumor therapeutic efficacy. In this review, we highlight the significant improvement of PTOX by the hybrid molecules in the structure diagram of each compound. Such compounds can improve the specificity of antitumor drugs, reduce side effects, and override drug resistance, making hybridization an excellent strategy for the advancement of novel anticancer drugs. At the molecular mechanism level, PTOX and its derivatives exhibit significant anticancer effects by inhibiting tubulin and DNA topoisomerase II, respectively, leading to cell cycle arrest and DNA breakage (Zhao et al., 2020). In addition, PTOX derivatives have selective high toxicity against various drug-resistant tumor cells. Nowadays, mounting researchers in the study of PTOX derivatives are now focusing on the interaction between PTOX and cancer-related signaling pathways, which will help develop more selective antitumor drugs with fewer systemic side effects. A drug delivery system (DDS) loaded with PTOX derivatives was also developed to address the drawback of poor bioavailability of PTOX derivatives and to enable the controlled release of PTOXbased drugs.

PTOX DERIVATIVES AS AN ANTICANCER DRUG FOR VARIOUS CANCERS
The excellent antitumor activity of PTOX derivatives has been widely investigated, and plenty of novel derivatives have been exploited and their function validated in different neoplasms. In this paper, we focus on the most widely studied tumors, such as breast cancer, lung cancer, hepatocellular carcinoma, and colorectal cancer.

Breast Cancer
The latest data from the International Agency for Research on Cancer (IARC) shows that breast cancer has become the most common malignancy in the world, posing a serious threat to women's health. Triple-negative breast cancer (TNBC) is the most aggressive type of breast cancer with a high rate of metastasis and recurrence, accounting for 15-20% of all diagnosed breast cancer cases (Foulkes et al., 2010). PTOX and its derivatives can inhibit the proliferation, migration, and invasion of breast cancer in vitro and in vivo, making it a promising selective treatment (Khaled et al., 2016). Acetylpodophyllotoxin Compound 1 (Figure 2) exhibited selective inhibitory activity on human breast cancer (BT-549) cell line (Peña-Morán et al., 2016). Similarly, PTOX piperazine acetate derivatives Compound 2 (Figure 2) showed highly selective damage to the human breast cancer (MCF-7) cell line by causing G2/M blockade and microtubule disruption, while no damage was observed in noncancerous cells . The 4β-amidopodophyllotoxins Compound 3 (Figure 2) induced cell cycle arrest, increased p53 and cyclin B1 protein expression, and decreased Cdk1 in MCF-7 cells, suggesting that these conjugates have an inhibitory effect on mitosis (Kamal et al., 2013). It was also observed that the expression of proteins that regulate the tumor microenvironment (e.g., VEGF-A, STAT-3, ERK1/2, ERK-p, etc.) was reduced after treatment of MCF-7 cells with these PTOX derivatives. This suggested that these PTOX derivatives may affect tumor angiogenesis and invasion.  synthesized a new orally PTOX derivative Compound 4 (Figure 2), XWL-1-48, which can bind to topoisomerase II through the formation of two strong hydrogen bonds and potential pi-pi interactions. XWL-1-48 exhibited robust antitumor activity in both in vitro and in vivo breast cancer models. It led to the production of ROS and γ-H2AX and activated the ATM/p53/p21 pathway to trigger DNA damage response in human breast cancer cells, and also induced mitochondrial apoptosis and cell cycle arrest. Zhang et al. (2020) comprehensively analyzed the molecular mechanism of PTOX on TNBC, and they suggested that PLK1 may be a downstream key gene. Furthermore, many drug delivery system (DDS)-based products were developed to improve aqueous solubility and reduce the side effects of PTOX. Li    anticancer efficacy against MCF-7/ADR xenograft tumors compared to controls.

Lung Cancer
Following breast cancer, lung cancer has the second-highest incidence rate of all cancers in the world and remains the leading cause of cancer death. Numerous studies have shown that PTOX and its derivatives can inhibit the growth of human lung cancer cells and induce apoptosis, cell cycle G2/M blockade, and ROS production (Passarella et al., 2008;Cho et al., 2016). Oh et al. (2021) investigated PTOX-induced apoptosis in human lung cancer cells and found that inhibition of c-MET kinase activity contributed to PTOX-induced cell death. Chen et al. (2013) developed a podophyllotoxin derivative Compound 6 (Figure 3), Ching001, which is specifically lethal to a variety of human lung cancer cell lines but has no significant cytotoxicity to normal human lung cell lines. The hybrids of PTOX and formononetin Compound 7 (Figure 3) displayed better inhibition of invasion and migration in human lung cancer (A549) cell line compared to the parent PTOX, and these PTOX derivatives induced apoptosis in A549 cells mainly through the caspase pathway . The tertiary amine-derived 4 -demethyl-epigallocatechin Compound 8 (Figure 3) adducts showed strong cytotoxicity against small cell lung cancer (SCLC) cell lines and non-small cell lung cancer (NSCLC) cell lines (Zhou et al., 2016). These PTOX-based conjugates selectively aggregated in the lung and significantly reduced toxicity to normal organs and gastrointestinal damage compared to VP-16. β-apopicropodophyllin (APP) Compound 9 (Figure 3) also showed potent anticancer activity against NSCLC cells (Kim et al., 2018). Molecularly, APP led to the accumulation of phosphorylated CHK2, p21, and phosphorylated Cdc2, disrupting microtubule polymerization and damaging DNA, and it stimulated the pro-apoptotic ER stress signaling pathway. Activation of caspase-3, -8, and -9 was also observed, suggesting that it may trigger both intrinsic and extrinsic apoptotic pathways in NSCLC cells. The 4β-cinnamic acidlinked PTOX Compound 10 ( Figure 3) adduct also had a DNA topoisomerase IIα inhibitory effect on A549 cells and induced mitochondria-mediated apoptosis. At the molecular level, apoptosis was accompanied by increased expression of poly ADP-ribose polymerase (PARP), caspase-3, and Bax and decreased expression of Bcl-2 (Kamal et al., 2015). Deoxypodophyllotoxin derivatives Compound 11 (Figure 3) also inhibited microtubule formation and induced cell cycle arrest in human lung cancer cells (Sang et al., 2013). Similarly, these PTOX derivatives induced Bax expression and cleaved caspase-3, and inhibited p53/cdc2/Bax signaling and Bcl-2 expression. In addition, PTOX acetate (PA) Compound 12 (Figure 3) was found to act as a radiosensitizer in NSCLC, which may be associated with an increased rate of ROS transformation (Choi et al., 2015b;Hong et al., 2016). In addition to reducing microtubule polymerization, inducing cell cycle arrest, and causing DNA damage, PA can trigger apoptotic pathways (including caspase-3, -8, and -9 pathway) and activate pro-apoptotic ER stress pathways (increasing the expression levels of BiP, CHOP, IRE1-α, phosphorylated PERK, and phosphorylated JNK). Furthermore, PA can activate autophagy in human lung cancer cells and increase the expression of beclin-1, Atg3, Atg5, and Atg7 as well as the cleavage of LC3.

Colorectal Cancer
Colorectal cancer (CRC), as one of the most common malignant diseases in developed countries, is the second leading cause of cancer death, and human CRC cell lines are commonly used in PTOX pharmacology studies. Bhat et al. (2008) synthesized 4β-[(4-substituted)-1,2,3-triazol-1-yl] PTOX derivatives Compound 13 (Figure 4) and found them to be cytotoxic against all seven human cancer cell lines, with a significant anticancer effect on human CRC (HCT-15 and 502713) cell lines in particular. Zhao et al. (2013) synthesized an aroylthiourea analog of PTOX, HY-1 Compound 14 (Figure 4) (4b-[benzoylthiourea]-4deoxypodophyllin), which can inhibit the proliferation of human CRC (HCT116) cell lines. In addition, HY-1 can target DNA topoisomerase II and induced cell apoptosis as well as cell cycle arrest. Western blotting showed that G2/M phase arrest was associated with decreased cdc2 kinase activity and increased cdc2 phosphorylation. 5-Fluorouracil (5-FU) is a conventional chemotherapeutic agent used for the treatment of CRC, but drug resistance and recurrent cases are frequently reported (Vodenkova et al., 2020). Katoch et al. (2021) revealed that the natural PTOX derivative 4 -demethyl-deoxypodophyllotoxin glucoside Compound 15 (Figure 4) had a significant inhibitory effect on tumor growth and metastasis in CRC cells and 5-FU-resistant cells, and effectively inhibited lung metastasis in an in situ mouse model of CRC. Moreover, Ha et al. (2021) designed and synthesized a supramolecular hydrogel, prodrug4a Compound 16 (Figure 4), consisting of PTOX and polyethylene glycol (PEG) chains. In particular, this compound can target the colon by selectively activating azoreductase. Furthermore, this compound can act as a nanodrug carrier to deliver 5-Fu, exhibiting significant synergistic cytotoxicity against CRC cells. However, the experiment needs to be evaluated in an animal model.

Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the major malignancy originating from the liver, accounting for approximately 80% of all types of liver cancer .   Figure 5) and found it to be more cytotoxic than VP-16 and doxorubicin against lung cancer, breast cancer, and liver cancer cells. Zi et al. (2018) synthesized a novel dimeric PTOX derivative Compound 20 ( Figure 5) and found it to have potent anticancer activity against leukemia, hepatoma, lung cancer, breast cancer, and colon cancer cells. In a nutshell, the excellent selective therapeutic effect of PTOX and its derivatives on a variety of tumors has attracted increasing attention. Besides the above mentioned tumors, researchers have further developed more PTOX derivatives against other different cancers as well, including pancreatic cancer (Pan et al., 2020), leukemia (Zhang et al., 2016b), head and neck squamous cell carcinoma (HNSCC) (Resendez et al., 2019), cervical carcinoma , etc.

MECHANISM OF PTOX DERIVATIVES AS AN ANTICANCER DRUG
The recognized anticancer mechanisms of PTOX and its derivatives are as inhibitors of tubulin and DNA topoisomerase II, respectively. In addition, mounting studies on PTOX derivatives have shown that multiple cancer-associated signaling pathways may intimately correlate with their anticancer ability (Figure 6).

Main Mechanism
Inhibitor of Tubulin PTOX, whose pharmacological effects have been recognized to inhibit microtubule assembly by blocking the colchicine binding site, thereby exhibiting inhibition of microtubule protein polymerization and inducing G2/M blockade, has shown potent antitumor activity (Cortese et al., 1977). PTOX derivatives have also been shown to have the analogous ability (Han et al., 2018). Kamal et al. (2011b) synthesized a series of conjugates of 4aza-2,3-didehydropodophyllotoxins Compound 21 (Figure 7), and fluorescent tubulin polymerization analysis showed these PTOX derivatives significantly reduced tubulin units. On the molecular mechanism, these PTOX-based conjugates caused apoptosis of A549 cancer cells in a caspase-3 dependent manner (Kamal et al., 2014). Likewise, Kandil et al. (2016) synthesized 4-azapodophyllotoxin derivatives Compound 22 (Figure 7), which induces disruption of the microtubule cytoskeleton at a sub-micromolar level to MCF-7 cancer cells. Similarly, 4β-[(5-substituted)-1,2,3,4-tetrazolyl] PTOX derivatives Compound 23 (Figure 7) were synthesized, which inhibited nearly 90% polymerization of tubulin at only 5 µM concentration (Hyder et al., 2015). Sadeghi et al. (2015) investigated the antitumor effect of 6-methoxyPTOX (MPTOX) Compound 24 (Figure 7), which has a similar structure to PTOX. Treatment of human bladder cancer (5637) cell line and myeloid leukemia (K562) cell line with MPTOX significantly reduced the viability of tumor cells and induced their programmed cell death. In addition, the expression of TUBB3 (a key member of β-tubulin) and TOPIIA (a key nuclease in DNA replication) was inhibited in tumor cells after MPTOX treatment. Furthermore, Bai et al. (2012) and Zhao et al. (2015Zhao et al. ( , 2019 demonstrated that the carbon-sulfur bond at the 4-position (C-4) of the carbon ring of PTOX reduced the inhibitory effect of dose on tubulin polymerization, thereby enhancing its therapeutic effect. They synthesized 4β-NH-(6aminoindole)-4-deoxy-PTOX Compound 25 (Figure 7) that can target the α-tubulin binding site and colchicine binding domain, as confirmed by X-ray crystallographic analysis. Importantly, these PTOX derivatives exhibited nanomolar antitumor efficacy in vitro and no significant toxicity in vivo.

Inhibitor of DNA Topoisomerase II
The severe side effects of PTOX, such as high toxicity and gastrointestinal upset, have limited its use in cancer chemotherapy. Extensive structural modifications of PTOX have yielded more effective and less toxic anticancer agents, such as etoposide and teniposide, which have been widely used in cancer chemotherapy (Evans et al., 1985;Paz-Ares et al., 2019). They stabilize the cleavage complex formed between the enzyme and its DNA substrate, thereby inhibiting topoisomerase II degradation and ultimately triggering cell death through the accumulation of chromosome breaks. Topoisomerases (topo-I and topo-II) play an important role in DNA replication, transcription and are a group of promising antitumor targets. Scholars generally believe that the bulky motif at the C-4 position of PTOX may be responsible for the inhibition of topo II (Stähelin and von Wartburg, 1991), and γ-H2AX is a classical marker of double-stranded DNA breaks during DNA damage (Kinner et al., 2008). Kamal et al. (2011a) developed the new PTOX analog 4β-acrylamidopodophyllotoxin congeners Compound 26 (Figure 8) as a potential anticancer agent. Their results showed that a large number of γ-H2AX foci were observed in etoposide and this PTOX derivative-treated cells, while double-stranded DNA breaks were negligible in PTOXtreated cells. Shankaraiah et al. (2015) developed a facile onepot method and successfully synthesized novel PTOX-thiourea hybrids Compound 27 (Figure 8), which showed selective DNA topoisomerase II inhibitory activity and anticancer activity against human prostate cancer (DU-145) cell line. In addition, the 4bβ-aminotriazole PTOX derivative Compound 28 (Figure 8) synthesized by Reddy et al. (2018) showed potent cytotoxicity on prostate cancer cell lines and was efficient in inhibiting DNA topoisomerase II. Likewise, β-carboline PTOX congeners Compound 29 (Figure 8) exhibited excellent cytotoxicity against human prostate cancer (DU-145) cell lines, and the DNA topoisomerase II inhibitory ability of these congeners was confirmed by comet analysis, DNA binding studies, and docking studies (Sathish et al., 2018).

Multidrug Resistance-Associated Molecules
In malignant chemotherapy, resistance to anticancer drugs can often be demonstrated and is usually manifested as multidrug resistance (MDR), which is one of the research hotspots in cancer prevention and treatment (Erin et al., 2020). The superfamily of transmembrane ATP-binding cassette (ABC) transporter proteins enhances the efflux of a wide range of chemotherapeutic agents and is regarded as one of the major causes of MDR in cancer, with the role of the highly expressed P-glycoprotein (P-gp) being the most well established (Zhang et al., 2021). Chen et al. (2009) synthesized a PTOX derivative, L1EPO Compound 30 (Figure 9), which exhibited cytotoxicity to P-gp-mediated MDR cancer cell lines (K562/A02 and KBv200) but was less cytotoxic  to normal human cell lines. Furthermore, L1EPO downregulated the mdr-1 gene and reduced the expression of P-gp, which may be the mechanism of its anti-MDR effect. Similarly, YB-1EPN Compound 31 (Figure 9) as a PTOX derivative also showed cytotoxicity against KBV200 and K562/A02 cells, while downregulating mdr-1 and bcl-2 expression, suggesting its ability to overcome P-gp-mediated MDR (Chen et al., 2010). Hu et al. (2010) synthesized a range of 4β-anilino-PTOX analogs Compound 32 (Figure 9) that led to G2/M phase arrest and eventually induced apoptosis in drug-resistant KB/VCR cancer cells. In both drug-sensitive xenograft models and drugresistant xenograft models, the administration of 4β-anilino-PTOX analogs can effectively treat cancer at lower doses than VP-16. In many other studies, it has been shown that 4β-anilino-PTOX analogs may kill MDR tumor cells (e.g., K562/A02) by downregulating mdr-1 expression (Cheng et al., 2014;Cao et al., 2015Cao et al., , 2018. Zhang et al. (2016a) synthesized pyridine acid esters of PTOX Compound 33 (Figure 9), which efficiently triggered cell cycle arrest and accompanied induction of apoptosis in K562/ADR tumor cells [resistant to adriamycin (ADR)]. Regarding the molecular mechanism, the results suggested that the pyridylate of PTOX may reduce the expression of the P-gp protein by stimulating the ERK1/2 signaling patway. In addition, aromatic heterocyclic esters of PTOX also showed potent anti-MDR activity against K562/ADR cancer cells, causing cellular S-phase block, apoptosis, and downregulation of P-gp expression, with molecular mechanisms suggesting an association with the ROS/MAPK pathway (Zhang et al., 2016b).
In addition, nanomedicine, which has been widely used in anti-cancer, can be used to modify PTOX derivatives to improve their poor solubility and high toxicity. Roy et al. (2015Roy et al. ( , 2017 developed PTOX-based nanomedicines by covalently coupling PTOX and polyethylene glycol (PEG) with acetylated carboxymethylcellulose (CMC-Ac) Compound 34 (Figure 9) via one-pot esterification chemistry. They prepared PTOXbased nanoparticles (NPs) with an average diameter of 20 nm, which released PTOX at ∼5%/day in serum. The NPs exhibited excellent killing ability and high selectivity for tumor cells, their accumulation in tumor tissues was eightfold higher than all other tissues, and they showed significantly improved efficacy against MDR tumors in mice with minimal systemic toxicity. Zhou et al. (2018) developed a peptide-based PTOX conjugated poly( L -glutamic acid)-g-methoxy poly(ethylene glycol) (PLG-g-mPEG) Compound 35 (Figure 9), which effectively inhibited the expression of P-gp in the MCF-7/ADR cancer cells. In vivo experiments showed that the PLG-g-mPEG-PTOX conjugate had excellent antitumor efficacy against MCF-7/ADR xenograft tumors with a tumor inhibition rate of 82.5%. Compared with free PTOX, it showed significantly higher anticancer efficacy with minimal toxicity. In addition, Feng et al. (2020) developed a pH/redox cascade-sensitive multiscale nanoparticle, PAMAM-ss-PPT, which can fully release PTOX in the presence of elevated glutathione (GSH). Results demonstrated that nanoparticles can effectively penetrate paclitaxel-resistant A549 cancer cell xenografts and inhibit tumor growth with negligible toxicity .

Glucose Metabolism-Associated Molecules
Glucose metabolism is a key feature of tumor cells, and their proliferation is accompanied by increased demand for energy and metabolic substrates. Many cancers are adapting to these demands through a shift in metabolism termed the Warburg effect, which inhibits oxidative phosphorylation and thus promotes a glucose-to-lactate aerobic fermentation (Vander Heiden et al., 2009 new PTOX derivative, SU212 Compound 46 (Figure 10), which exhibited selective anticancer toxicity through direct activation of AMP-activated protein kinase (AMPK). Moreover, this PTOX derivative could regulate the Warburg effect in triple-negative breast cancer cells through the AMPK/hypoxia-inducible factor 1α (HIF-1α) pathway, suggesting the potential research interest of PTOX derivatives in the field of tumor glycolysis.

CONCLUSION AND PERSPECTIVES
In conclusion, PTOX derivatives have shown significant anticancer properties through modification with various natural substances or nanomaterials, and some of them are already used in clinical practice. Currently, most of the molecular structure modifications of PTOX are focused on its C-4 position, and the primary function of these designed PTOX derivatives is to act as inhibitors of tubulin polymerization or topoisomerase II, thereby inducing cell cycle arrest and DNA breakage. In addition, many promising PTOX hybrids may serve as novel anticancer candidates with dual or multiple anticancer mechanisms, such as affecting MDR, apoptosis, autophagy, EMT-related pathway, and glycolysis of cancers. However, the specific anticancer mechanism remains to be refined, which is important for the development of next-generation novel PTOX derivatives. Identification of cancer-related signaling pathways can significantly improve patient outcomes through the development of targeted novel chemotherapeutic agents. Furthermore, with the advancement of nanomedicine, novel PTOX-based drug delivery systems can be developed, and multiple therapeutic approaches can be combined. Drug delivery system approaches have been shown to significantly improve the pharmacological properties of established drugs, and several delivery technologies for chemotherapeutic drugs have entered the clinic (Manzari et al., 2021). For example, in 1995, the FDA approved the first nanoparticle drug formulation, doxorubicin-liposome, which greatly reduced the heart toxicity of doxorubicin (Gabizon et al., 2003). Also, patisiran-lipid nanoparticles, a novel nanocomplex for the treatment of amyloidosis (Clinical trial number NCT01960348), was the first siRNA therapy approved by the FDA in 2018. However, there are still very few nanomedicines entering clinical applications compared to existing studies, possibly due in part to low drug loading and delivery efficiency. With recent advances in computerbased artificial intelligence algorithms that could facilitate the development of nanoparticles, these issues may be addressed in the near future. As a natural product with multiple biological activities, the outstanding potentiality of PTOX will hopefully contribute to the development of optimal anticancer drugs.

AUTHOR CONTRIBUTIONS
YL-T, YJ-T, and XH-L contributed to conception and design of the study. HY-F organized the database. HY-F and HC-X wrote the first draft of the manuscript. HF-W and BJ-C wrote sections of the manuscript. ZL-Z made major contributions to manuscript revision. All authors contributed to manuscript revision, read, and approved the submitted version.

FUNDING
This work was supported by financial supports from the National Key R&D Program of China (No. 2021YFC2101500), the National Natural Science Foundation of China grants (Nos. 82073000 and 81972542), and the National Science Foundation of Sichuan Province (Nos. 2020JDRC0018 and 2020YFS0171).